Objective: To assess the effectiveness of cotrimoxazole preventive therapy (CPT) among individuals with CD4 cell count above 200 cells/ml and varying WHO clinical stages in reducing mortality during combination antiretroviral therapy (cART).
Introduction
Primary prophylaxis with cotrimoxazole (trimethoprimsulfamethoxazole) is recommended for persons living with HIV to reduce morbidity and mortality. In industrialized countries, cotrimoxazole preventive therapy (CPT) is principally used to prevent Pneumocystis jirovecii infection among individuals with CD4 cell counts below 200 cells/ml and toxoplasmosis among individuals with CD4 cell counts below 100 cells/ml [1] . In resourcelimited settings, the main benefit from CPT arises less from prevention of the classic opportunistic infections, Pneumocystis pneumonia, and toxoplasmosis, but primarily from prevention of severe disease from malaria, bacterial pneumonia and sepsis, and diarrhea [2, 3] . Thus, the benefit among adults in settings in which these diseases are common extends above a CD4 cell count threshold of 200 cells/ml [2] [3] [4] . The WHO guidelines for CPT use in resource-limited settings reflect the extended CD4 range of benefit and recommend CPT for adolescents and adults with CD4 cell count below 350 cells/ml or WHO clinical stage 3 or 4 disease (or WHO clinical stage 2, 3, or 4 when CD4 assays are not available) [5] . The evidence driving these guidelines has primarily been derived from regions with high malaria burden and possibly lower bacterial resistance to cotrimoxazole [2] [3] [4] . Perhaps as a result, the WHO guidelines direct the recommendation for use of CPT, 'particularly in resource-limited settings in which bacterial infections and malaria are prevalent among people living with HIV' [5] . In addition, the majority of studies assessing CPT in resource-limited settings were conducted prior to the availability of combination antiretroviral therapy (cART).
Uncertainty exists regarding the most effective use of CPT among patients receiving cART, especially among those living in areas without prevalent malaria or with a high prevalence of cotrimoxazole resistance among common bacterial pathogens [5] [6] [7] [8] [9] . Because individuals often have rapid increases in CD4 cell count after cART initiation and because high initial early mortality may be attributed to conditions present at the time of cART initiation [10] [11] [12] [13] , clinicians may also place less emphasis on CPT in cART initiators. However, the high mortality early after cART initiation calls for optimizing management. Improved recognition of which patients may benefit from CPT, in all resource-limited regions, is needed to both focus effort where most beneficial and avoid providing an agent with potential toxicity to individuals who are unlikely to benefit. To extend the evidence base, we sought to evaluate the effectiveness of CPT at cART initiation on reducing mortality at CD4 cell counts above and below 200 cells/ml in a large South African cohort with minimal exposure to malaria but with high reported rates of cotrimoxazole-resistant bacteria [8, 9, [14] [15] [16] .
Methods

Patients
Patients included in this study were enrolled in a multisite community and workplace-based HIV cART treatment management program in South Africa and met the following criteria: initiated cART between January 2003 and January 2008, were at least 18 years old, were ART naive at cART initiation, had a CD4 assay result within 6 months prior to cART initiation, and started CPT less than 30 days before or less than 7 days after starting cART or did not receive any CPT during the first 12 months of cART. We included all eligible patients in our analysis.
Antiretroviral therapy programs
The study cohort was recruited from 231 community and workplace-based ART clinics. Patients from the workplace-based clinics started cART from January 2003 onwards, whereas patients in the community-based clinics started cART from January 2004 onwards. The number of patients meeting inclusion criteria from a given clinic varied between 1 and 1432 individuals. For the 67 workplace-based clinics, cART eligibility was based on CD4 cell count below 250 cells/ml, WHO stage 3 and CD4 cell count below 350 cells/ml, or WHO stage 4 condition. For the 164 community-based clinics, cART eligibility was CD4 cell count below 200 cells/ml or WHO stage 4 condition. The first-line regimen was either zidovudine or stavudine/lamivudine, and either efavirenz or nevirapine. CPT use was initially recommended for patients with CD4 cell count below 200 cells/ml, for consistency with international guidelines. In 2005, this was changed, at all sites, to CD4 cell count below 350 cells/ml or any WHO stage 3 or 4 condition for consistency with WHO recommendations [5] . There was no specific policy at any time to discontinue CPT after reaching a certain CD4 cell count threshold. Actual clinical practice regarding CPT initiation and discontinuation varied considerably. Isoniazid preventive therapy for the treatment of latent tuberculosis (TB) infection was recommended for all individuals who had no symptoms suggestive of active TB and no treatment for TB within the prior 2 years. All clinics used similar monitoring schedules with HIV RNA and CD4 cell count determined before cART initiation, after 6 weeks on cART, and every 6 months.
Ethical approval for this study was obtained from the London School for Hygiene and Tropical Medicine and the University of KwaZulu-Natal.
Death ascertainment
We used three methods of ascertaining death: deregistration forms, which record reasons for discontinuation of cART, including death; active tracing of defaulters not returning within 6 months of the last clinic visit; and in the workplace programs, human resources data to identify workers who either died or were separated from employment. Workers who were terminally ill and were unable to report to work for 3-6 months and were not expected to return to work within another 12 months were medically separated from employment and were referred to community clinics for care. To minimize underascertainment of death as a result of work separations of terminally ill individuals, we included medical separations as a death surrogate for a combined mortality endpoint.
Definitions
Combination antiretroviral therapy cART includes two nucleoside reverse transcriptase inhibitors and either a nonnucleoside reverse transcriptase inhibitor or a protease inhibitor.
Cotrimoxazole preventive therapy
The standard dose of cotrimoxazole used for CPT was sulfamethoxazole 800 mg and trimethoprim 160 mg daily. Individuals starting CPT less than 30 days before and less than 7 days after cART initiation were analyzed within the CPT group, even if they discontinued CPT prior to the end of the observation period. This approach was selected because the goal of the analysis was to assess the effectiveness of including CPT at cART initiation and because the risk for death declines during cART therapy and many individuals who initially received CPT discontinued use over time.
Loss to follow-up
Absence of any further clinic visits for more than 6 months after the last documented visit.
Laboratory
HIV RNAwas assayed by PCR (Amplicor HIV-1 Monitor
Test, Roche Diagnostics, Nutley, New Jersey, USA). Absolute CD4 cell counts were assayed by flow cytometry (Becton Dickinson, Mountain View, California, USA). All laboratory tests were performed at commercial certified laboratories in South Africa.
Statistical analysis
We evaluated the following variables measured at the start of cART: age, sex, log 10 HIV RNA, absolute CD4 cell count, WHO clinical stage, history of prior TB disease, isoniazid preventive therapy, and CPT use; and the following time updated variables: absolute CD4 cell count and HIV RNA suppression (defined as HIV RNA <400 copies/ml). If the CD4 cell count was not available from the last time period during evaluation, the latest available CD4 cell count was carried forward. CD4 cell count at cART initiation was stratified as below 200, 200-350, and above 350 cells/ml to focus on the question of whether CPT reduces mortality at higher CD4 cell counts.
Baseline factors were compared by CPT group, using either the percentage or median with the x 2 test or Wilcoxon rank sum test, as appropriate. Kaplan-Meier survival functions were used to calculate survival probabilities for the first 12 months of cART. Cox proportional hazards modeling was used to evaluate the effect of CPT receipt on survival during cART. CPT use was defined as a fixed (not time updated) variable during the entire observation period. Univariable and multivariable associations were assessed with the combined mortality endpoint over the observation period that started at cART initiation and continued until the earlier of 12 months, discontinuation of cART, last follow-up visit, or death or termination of employment due to terminal illness. We initially assessed for association between factors and mortality in univariable analysis. Factors that either affected the hazard ratio for CPT (confounders) or were indications for CPT use were included in an adjusted multivariable model; in addition, we included age and sex, a priori, in the model. Factors statistically associated with mortality but that neither affected the association between CPT and mortality nor were indications for CPTuse were not included in the adjusted analysis, as the objective of this analysis was to describe the effect of CPTon mortality. The proportional hazards assumption was assessed and a P value of less than 0.1 used to define failure to meet the proportional hazards assumption. To assess for association between CPT and mortality at differing baseline CD4 cell counts, we modeled an interaction between CPT and baseline CD4 cell count strata. We further restricted analysis to patients with WHO stage 1 or 2 at cART initiation to better identify patients most likely to benefit from CPT. We also performed a sensitivity analysis only using known deaths (excluding medical separations). All univariable and multivariable modeling included clinic site as a random effect (proportional hazards model with frailty) to control for residual clinic level confounding and potential clustering at clinic level.
Results
Patients
Out of a total of 16 068 cART initiators, we included 14 097 with a total of 10 751 person-years of observation and a mean duration of follow-up of 9.2 months. Of the excluded patients, 401 were excluded because they started CPT after cART initiation, 462 were excluded because they started CPT more than 30 days before cART initiation, and 1108 were excluded because they lacked CD4 cell count data within 6 months prior to cART initiation. CPT receipt among patients included and those excluded due to missing CD4 cell count data were similar (55 and 57%, respectively). Of the included patients, 8696 (62%) were men, the median age was 39 years [interquartile range (IQR) 33-46], and median CD4 cell count was 132 (IQR 60-206) at cART initiation (Table 1) . CPT was started among 7508 (53%) patients. The median CD4 cell count at baseline was lower among CPT recipients (118 cells/ml, IQR 53-184) than those who did not receive CPT (153 cells/ml, IQR 70-236, P < 0.001). The mean time on CPT was 9 months [95% confidence interval (CI) 8.8-9.2] with a ratio of time receiving CPT to follow-up time of 0.62. One thousand, one hundred and eighty-six (18%) individuals not receiving CPT compared with 901 (12%) receiving CPT discontinued cART, left care, or were lost to follow-up (censored) before the end of the observation period (P < 0.001).
Mortality
During the observation period, 1137 patients died and 152 were medically separated (1289 total events in combined endpoint). In univariable analysis, the following were associated with decreased mortality ( Table 2) : receipt of CPT (hazard ratio 0.60, 95% CI 0.53-0.68), younger age (P ¼ 0.03), female sex (P < 0.001), higher baseline CD4 cell count (P < 0.001), receipt of isoniazid preventive therapy (P < 0.001), higher time-updated CD4 cell count (P < 0.001), virologic suppression during follow-up (P < 0.001), and lower baseline WHO clinical stage (P < 0.001).
We assessed the proportional hazards assumptions for each covariate. CD4 cell count at cART initiation failed to meet proportional hazards assumptions (interaction with cART duration) (P ¼ 0.04). However, as our goal was to model the effectiveness of CPT by different CD4 cell count strata at cART initiation, we included CD4 cell count at cART initiation in the final model. All the other covariates met the proportional hazards assumption (interaction with duration on cART, P > 0.1). In addition, there were no interactions between the effect of CPT on mortality and any of the other covariates (P > 0.1).
Mortality and cotrimoxazole
The adjusted model included baseline CD4 cell count group, time-updated HIV RNA suppression, history of prior TB, WHO stage at cART initiation, sex, age, and receipt of CPT (Table 2 ). These factors were selected, as described in the Methods, to include covariates that either were indications for CPT use or affected the association between CPTand mortality. Neither isoniazid preventive therapy nor time-updated CD4 cell count affected the hazard ratio for CPT in an adjusted model. In the final adjusted model, CPT use remained strongly associated with decreased mortality (adjusted hazard ratio 0.64, 95% CI 0.57-0.72, P < 0.001).
Cotrimoxazole use, CD4 cell count, and WHO clinical stage at combination antiretroviral therapy initiation We graphically evaluated the impact of CPT by baseline CD4 cell count group via Kaplan-Meier survival curves ( Fig. 1 ). To assess for differences in association between CPTand mortality by baseline CD4 cell count, we assessed for an interaction (effect modification). When including patients in all WHO stages, data were consistent with no effect modification of CPT by CD4 cell count strata (P ¼ 0.8), indicating a similar association between CPTand mortality across the three baseline CD4 cell count groups. The adjusted association of CPTon mortality stratified by CD4 cell count group at cART initiation was as follows: CD4 cell count below 200 cells/ml [hazard ratio 0.64 (95% CI 0.56-0.72)], CD4 cell count 200-350 cells/ml [hazard ratio 0.62 (95% CI 0.41-0.94)], and CD4 cell count above 350 cells/ml [hazard ratio 0.80 (95% CI 0.38-1.7)] ( Table 3 ). We also restricted analysis to patients with WHO stages 1 and 2 at baseline to address the question of whether CPT has a measurable impact among individuals with higher CD4 cell count and no history of WHO clinical stage 3 or 4 conditions. Limiting the analysis to patients with WHO clinical stage 1 or 2 disease resulted in the hazard ratios for CPTand mortality becoming close to, 1712 AIDS 2010, Vol 24 No 11 Finally, we performed a sensitivity analysis, limiting events to known deaths and not counting medical separations as mortality events, and had similar findings to the combined endpoint of association between CPT and mortality by CD4 cell count at cART initiation (not shown).
Discussion
We have demonstrated a 36% reduction in mortality when cotrimoxazole was included at cART initiation. This is an important finding, as the majority of studies from resource-limited settings evaluating CPT involved individuals not yet on cART. Importantly, the reduction Cotrimoxazole with antiretroviral therapy Hoffmann et al. 1713 in mortality was seen at all CD4 cell counts at cART initiation among individuals unrestricted by WHO clinical stage. This demonstrates a wide range of benefit from cotrimoxazole in South Africa despite low levels of malaria, P. jirovecii infection, and high levels of bacterial resistance to cotrimoxazole [14] [15] [16] [17] [18] . In addition, it suggests that the WHO cotrimoxazole recommendations have broad applicability among cART initiators in differing African settings.
Our findings build on several studies [2] [3] [4] [19] [20] [21] of adults not receiving cART and one study [22] of adult cART recipients. A study [4] conducted in the pre-cART era in the Ivory Coast randomized patients with both HIV and TB (WHO stage 3 or 4 disease) to receive either CPT or placebo. In that study, the use of CPTreduced mortality by 46%. In subgroup analysis, the benefit was statistically significant up to a CD4 cell count of 350 cells/ml. Two other studies [18, 20] also focusing on CPT among TB patients, one from Zambia and the other from South Africa, also identified mortality reduction with CPTuse, with hazard ratios of 0.79 and 0.68, respectively. Neither of these studies presented results stratified by CD4 cell count.
Two cohort studies from pre-ART adult populations, with or without a history of TB, also identified a benefit at lower CD4 cell counts and more advanced disease, but little mortality reduction among individuals with higher CD4 cell counts. A study [3] from Uganda identified an association between CPT and mortality with a hazard ratio of 0.54. However, the association was statistically significant only for individuals with CD4 cell count below 200 cells/ml or WHO clinical stage 3 or 4 disease. Very similar results regarding benefit only at lower CD4 cell counts were reported from a pre-ART cohort [16] in South Africa in which CPT reduced mortality with a hazard ratio of 0.56.
The one on-cART study [19] was a clinic-level comparison performed in Malawi. In that study, the hazard ratio for 6-month mortality comparing clinics dispensing CPT and those not dispensing CPT was 0.68.
As it was a clinic-level comparison, results could not be stratified by CD4 cell count.
A study [2] that did not demonstrate reduced mortality from CPT was a clinical trial from the Ivory Coast that was stopped early based on predetermined differences in the combined endpoint of mortality and any hospitalization. The researchers did identify higher rates of pneumonia, diarrhea associated with isosporiasis, malaria, fevers, and bacteremia in the placebo group with an overall hazard ratio for events in the CPT arm of 0.57. The reduction in events was seen for all CD4 cell count strata; no stratification by WHO clinical stage was reported.
Our results are perhaps remarkable in their consistency with prior findings from regions with higher prevalence of malaria and diarrheal disease and some with reportedly lower prevalence of cotrimoxazole-resistant bacteria. Thus, they both help to generalize evidence for CPT use across African settings to individuals with CD4 cell counts above 200 cells/ml and to extend the findings to cART initiators. In addition, we have identified a group of individuals who may not benefit from CPT in our setting, individuals with both CD4 cell count above 200 cells/ml and WHO clinical stage 1 or 2 disease. As those individuals had a low likelihood of benefit, the risk for adverse reactions related to cotrimoxazole may be greater than clinical benefit.
Our study is further important because the large size of the study population with 14 097 cART initiators and 1289 events provided power to identify even small differences in mortality. However, several limitations are worth noting. First, it is an observational cohort analysis and individuals were not randomly assigned to receive CPT. As a result, despite adjusting for multiple factors, residual confounding could remain and affect the results. As CPT is generally reserved for individuals with more 1714 AIDS 2010, Vol 24 No 11 advanced HIV, residual confounding may be more likely to lead to a finding of nonbenefit or increased mortality with CPT rather than the benefit we observed. We believe that clinic level effects regarding CPT use and mortality, such as both better care and CPT use, are unlikely to be driving the association because we adjusted for clinic site in all analyses. A strength of our cohort is the extensive ascertainment of deaths via human resources records in the workplace cohort and follow-up of individuals and deregistration of individuals who died. However, we likely have underascertained mortality with greater absolute numbers underascertained in the non-CPT group, the group with higher mortality. This is suggested by the higher proportion censored in the non-CPT group. We believe that underascertainment of death could reduce our power, but if it affected the strength of association, it would be to bias toward the null hypothesis.
Another limitation is that we did not identify cause of death, thus we are unable to describe the specific causes of death that CPT reduced. However, as our goal was to assess the overall effectiveness of CPT, cause of death was not a focus. Finally, we did not assess adherence to CPT; however, our goal was to evaluate CPT in a routine clinical setting with expected variation in adherence.
Although we do not have data on the cause of death for the patients in our study, we believe that the effect size of CPT is plausible based on available data on cause of death among persons living with HIV in Africa. Bacterial pathogens, especially Salmonella species and Streptococcus pneumoniae, Pneumocystis pneumonia, and diarrhea have been reported to be present at death among 18-50% of persons with HIV in southern Africa [17, 18, 23, 24] . Of note, the studies reporting the highest fraction of bacterial infections also had the most complete microbiological culture ascertainment. Thus, we speculate that bacterial infection, either in isolation or in coinfection with other diseases, was a major contributor to mortality in our population, and that use of CPT reduced this cause of death.
Our findings will be important to help guide clinicians in deciding when to use CPT in conjunction with cART.
Our results indicate that, in resource-limited settings, CPT should be started among all adults with a CD4 cell count below 200 cells/ml or WHO clinical stage 3 or 4. This message is critically important as early mortality during cART is, at times, viewed as a consequence of preexisting illness and not amenable to prevention with prophylactic therapies. As the majority of cART initiators, in our and other cohorts in Africa, start with a CD4 cell count considerably below 200 cells/ml, this is a simple and immediately implementable intervention to reduce high early mortality after cART initiation. A second important question concerns when CPT can be safely discontinued. In our cohort, most patients received approximately 9 months of CPT. However, we have not assessed to optimal time to discontinuation of CPT and can only speculate that 9-12 months, or more, may be appropriate. Given the low cost and profound impact on mortality, efforts should be redoubled to achieve high levels of CPTuptake within cART programs at, or before, cART initiation.
